The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Chris Allen Named CFO of $6B UChicago Medicine

Chris Allen stepped into the role of executive vice president and CFO at UChicago Medicine on Sept. 1, 2025, according to Becker's Hospital Review. The appointment marks a return to familiar ground: Allen began his career at the University of Chicago as a budget analyst in the Basic Science Division in the mid-1990s before moving on to build his finance career elsewhere.

Allen described the homecoming as surreal, noting that the executive suite he now occupies sits in a place he once walked as a junior analyst decades ago. He now oversees finance for an academic health system with roughly $6 billion in operations.

The hire lands as large academic medical centers navigate thin margins, rising labor and supply costs, and heavy capital demands. Systems of this scale increasingly seek CFOs who combine deep institutional knowledge with broad operating experience to steer strategy, investment, and financial discipline through an uncertain period for hospital finances.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.